43 articles
Event-contract revenue at Robinhood rose more than sixfold to $173M in Q3, while MiCA pushed Coinbase to convert non-compliant stablecoins. Most of this shift is being decided in the US; Europe's role so far is rule-taker. Figures come from SEC filings and dated documents.
Micron's verified filings show capital spending nearly doubling in a year and cash more than doubling. The European exposure in our data is narrow: ASML, Kalray and Bull. Much of the bullish commentary comes from sources whose past claims held up well under half the time.
Fintech money is moving toward AI-agent identity, payments and trading products. Our dossier is thin on EU specifics, so we say so. What it does hold is checked: Robinhood's SEC-filed results, a $35M identity round, and a Norwest investor's warning that AI should not do the maths.
Robinhood's event-contract revenue rose more than sixfold to $173M in Q3, and Nasdaq, Cboe and the CFTC are all moving toward round-the-clock trading. Europe's visible part in the dossier is MiCA's stablecoin deadline. We checked Robinhood's figures against SEC filings.
Stockholm-based BioArctic's Leqembi royalty rose about 10% in Q2 2026. Idorsia is building its deal-making team. Incyte, Vor and others report data, but the sources vary in reliability, and we flag which claims are measured and which are company statements.
Lam Research guides to an $8.6B quarter on AI chip-equipment demand, while Dow leans on cost cuts against what its CFO calls persistently high energy costs. We checked Dow's multi-year figures against SEC filings. They show why European industry is exposed to the second story, not the first.
Third-quarter calls from Lam Research, Dow and Union Pacific show a split economy. AI-driven chip demand is outrunning supply, while industrials rely on cost cuts against high energy and fuel prices. Dow's comments on European energy costs are the most direct link to European readers. Figures come from SEC-checked data and verbatim call quotes.
Dow told investors that persistently high energy costs challenge European industry economics, while Union Pacific reported fuel costs up 69%. This piece uses fidelity-checked SEC data and named, dated earnings-call quotes. It shows where the dossier is strong and where it is thin on Europe.
Dow's CFO cites $1.1B of quarterly free cash flow and no big debt maturities until 2029, while Union Pacific's fuel bill jumped 69%. Both lean on self-help and balance-sheet strength. Figures come from SEC filings and earnings-call transcripts; the transcript source is reliable only about 60% of the time.
Via News tracked a US-led fintech wave, from retail event contracts to AI-agent identity startups. Little of it is European, and the dossier names no EU regulator. We lead with Robinhood's SEC-checked figures and flag where sources diverge or are weak.
Salesforce, ServiceNow and others are rebuilding around autonomous AI agents, and governance is becoming the selling point. The dossier holds no EU-specific regulatory facts, so we say so. What it does hold is SEC-verified Salesforce financials and primary announcements.
Europe's drug regulator issued positive opinions on RASONQUE, Libtayo dosing and Trodelvy plus Keytruda this summer and autumn, just before ESMO opens in Madrid. SEC-checked figures for Summit Therapeutics show what the pipeline costs. We flag where the evidence is thin or the sources are weak.
Analysts turned more bullish on Palantir in mid-October 2026 while J.P. Morgan's lead defence analyst downgraded Leidos and warned of a weak sector. The dossier holds little European regulatory material, so we say so, and set out what was said, by whom, and how reliable the sources are.
EU regulators backed a new Libtayo dosing schedule and a Trodelvy-Keytruda combination, while US dates for Summit's ivonescimab loom. AstraZeneca's AI drug-design vision rests on forecasts, not results. Summit's checked SEC filings show the cost of a late-stage bet.
Analysts are upgrading Palantir while J.P. Morgan warns on defence stocks. The dossier holds little European-specific evidence, so we say so. We separate verified figures, analyst opinion and our own reading, and flag where the sources are weak.
EU regulators are backing newer cancer treatments, and AI is billed as the long-term engine. But the one company with checked SEC figures, Summit Therapeutics, lost $1.08 billion in FY2025 with no revenue. Several AI claims are forecasts from a source that failed our reliability check.
AI spending is spreading from chips to networking, physical-world data and customer-service software. Nvidia's audited cost of sales shows how fast. The dossier says little about EU rules, and safety scrutiny of OpenAI is rising. Verified filings are separated from company claims.
SAP, Zeta and others are launching agent platforms, while the smaller deals show money flowing to the layers that keep agents in check. Our dossier has little on EU regulation, so we say so. It does contain a clear argument that rules must be enforced by the system, and a warning not to trust AI with finance arithmetic.
A CHMP opinion for Trodelvy, a German-first Optune Pax launch and real-world German data on mogamulizumab give Europe its own oncology story in a US-heavy October. Summit's SEC-verified accounts show how costly the biggest catalyst, ivonescimab, is to reach. Some sources here fared poorly in our reliability checks.
A French networking tie-up and a Dutch equipment maker sit at the European edge of an AI-driven memory and interconnect squeeze. SEC-verified Micron filings show how fast its spending has grown. We separate the checked figures from analyst opinion and flag where the sources are weak.
